Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-07-27 | antigen-specific Type 1 Treg cell therapy | TxCell (France) | Crohn disease |
Granting of a Fast Track status |
2015-04-15 | ivabradine | Amgen (USA - CA) | chronic heart failure |
Granting of a Market Authorisation in the US |
2017-07-21 | lacosamide | UCB (Belgium) | partial-onset seizures in adults with epilepsy - monotherapy and adjunctive therapy in children aged 4 years and older with epilepsy | Positive opinion for the granting of a Market Authorisation in the EU |
2015-06-18 | glatiramer acetate injection | Momenta Pharmaceuticals (USA - MA) Sandoz (Switzerland) | relapsing-remitting multiple sclerosis (RRMS) |
Product launch |
2014-09-05 | relebactam | Merck&Co (USA - NJ) | complicated urinary tract infections complicated intra-abdominal infections hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia |
Granting of a Fast Track status |
2015-01-08 | Debiopharm (Switzerland) | acute bacterial skin and skin structure infections (ABSSSI) |
Granting of a Fast Track status | |
2014-09-05 | ubiquitin-specific proteases (USP) | Hybrigenics (France) | Granting of a patent | |
2014-09-05 | ethiodized oil | Guerbet (France) | chemoembolization of tumors in adults with known, intermediate-stage hepatocellular carcinoma |
Granting of a Market Authorisation in the EU |
2015-12-18 | talimogene laherparepvec | Amgen (USA - CA) | local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery |
Granting of a Market Authorisation in the EU |
2014-11-25 | 2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid | Arena Pharmaceuticals (USA - CA) | pulmonary arterial hypertension (PAH) | Granting of a patent |
2014-09-06 | Clostridium difficile (C. difficile) vaccine | Pfizer (USA - NY) | Clostridium difficile infection |
Granting of a Fast Track status |
2014-09-06 | vemurafenib | Genentech (USA - CA), a member of Roche Group (Switzerland) | hairy cell leukemia (HCL) | Granting of the orphan status in the US |
2014-09-06 | recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor | Novartis (Switzerland) | pigmented villonodular synovitis, including giant cell tumor of the tendon sheath |
Granting of a patent |
2014-08-19 | olaptesed pegol | Noxxon Pharma (Germany) | glioblastoma |
Granting of the orphan status in the EU |
2014-08-25 | oprozomib | Onyx Therapeutics (USA - CA) Amgen (USA - CA) | Waldenstrom's macroglobulinemia |
Granting of the orphan status in the US |
2017-12-14 | darvadstrocel - adipose derived allogeneic stem cell therapy | Tigenix (Belgium) | complex perianal fistulas in patients with Crohn's disease | Positive opinion for the granting of a Market Authorisation in the EU |
2014-09-11 | hematopoietic stem and progenitor cells expanded ex-vivo with a low molecular weight aryl hydrocarbon receptor (AHR) antagonist | Novartis (Switzerland) | hematopoietic support in patients with acute lymphoblastic leukemia (ALL) |
Granting of the orphan status in the US |
2014-09-11 | mitomycin and sterile hydrogel composed of poloxamer 407, hydroxypropyl methyl cellulose and polyethylene glycol 400 | TheraCoat (Israel) | Granting of the orphan status in the US | |
2014-09-11 | vemurafenib | Genentech (USA - CA), a member of Roche Group (Switzerland) | non-small cell lung cancer (NSCLC) with BRAF V600E mutation | Granting of the orphan status in the US |
2014-09-04 | 6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one | Pfizer (USA - NY) | sickle cell disease |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+